Back to discover
Drug

Bupivacaine

Approved · EMA
ClassSodium channel protein type IV alpha subunit blockerEmerging researchLate-stage developmentSteady momentum
Also known as (RS)-bupivacaine, 1-Butyl-2',6'-pipecoloxylidide, DL-Bupivacaine, Exparel+20 more

(RS)-bupivacaine, 1-Butyl-2',6'-pipecoloxylidide, DL-Bupivacaine, Exparel, Marcaine, Marcaine with Epinephrine, Nocita, Posimir, Racemic bupivacaine, Sensorcaine, Sensorcaine with Epinephrine, Vivacaine, Xaracoll, Zynrelef, dl-1-Butyl-2',6'-pipecoloxylidide, (-)-bupivacaine, (±)-bupivacaine, Bupivacain, Bupivacaina, Bupivicaine, bupivakain, 1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide, Bupivacaine Hydrochloride, Bupivacainum.

4
Research papers
26
Active clinical trials
SCN4A
Primary target
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Latest Advances in Regional Anaesthesia.

Research2024-04-28Medicina (Kaunas, Lithuania)

Approval: Exparel liposomal (EMA)

Regulatory2020-11-16EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Bupivacaine
Aliases & brands
(RS)-bupivacaine1-Butyl-2',6'-pipecoloxylidideDL-BupivacaineExparelMarcaineMarcaine with EpinephrineNocitaPosimirRacemic bupivacaineSensorcaineSensorcaine with EpinephrineVivacaineXaracollZynrelefdl-1-Butyl-2',6'-pipecoloxylidide(-)-bupivacaine(±)-bupivacaineBupivacainBupivacainaBupivicainebupivakain1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamideBupivacaine HydrochlorideBupivacainum
RxNorm CUI
1815
ChEMBL ID
CHEMBL1098
ATC codes
N01BB01N01BB51
UNII
Y8335394RO
Primary mechanism
Sodium channel protein type IV alpha subunit blocker
Regulatory jurisdictions
ema

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

BLOCKERSodium channel protein type IV alpha subunit blocker

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2020-11-16
Latest approval
2020-11-16
Authorities
EMA
Total events
1
emaEuropean Medicines Agency· 1 event
2020-11-16Approval
Approval: Exparel liposomal (EMA)
Indication: Exparel liposomal is indicated: in adults as a brachial plexus block or femoral nerve block for treatment of post-operative pain. in adults and children aged 6 years orShow full indication

Exparel liposomal is indicated: in adults as a brachial plexus block or femoral nerve block for treatment of post-operative pain. in adults and children aged 6 years or older as a field block for treatment of somatic post-operative pain from small- to medium-sized surgical wounds.

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Clinical trials

193 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
193
registered trials across all phases
LATEST COMPLETION 2026
26
Active studies
25
Recruiting
162
Late-stage (III+)
113
Completed
54
Discontinued
PHASE DISTRIBUTIONn = 193
Early Phase 13Phase 111Phase 1 / 23Phase 214Phase 2 / 310Phase 319Phase 462Phase N / A71

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Recent completions

Trials that read out recently, adding to the completed evidence base.

Research activity

4 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20142024
Major research themes3
Anesthesia, Conduction1Bone Transplantation1Spinal Fusion1
Journals, researchers & institutions
Top journals
  • Gynecologic oncology1
  • Medicina (Kaunas, Lithuania)1
  • Orthopedics1
  • Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery1
Leading researchers
  • Akusoba I1
  • Bible JE1
  • Boone K1
  • Buggy DJ1
  • Carson L1
  • Crosby CG1
  • Crowe GG1
  • Delaney D1
Leading institutions
free-text, unnormalised
  • Cork University Hospital1
  • Fresno Heart and Surgical Hospital1
  • Masonic Cancer Center Biostatistics and Bioinformatics1
  • Mater Misericordiae University Hospital1
  • National Orthopaedic Hospital Cappagh/Mater Misericordiae University Hospital1
  • School of Medicine1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.